Valeria Varzieva

Ms. Valeria Varzieva

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2024 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
VVValeria Varzieva
Valeria Varzieva
NMNatalia Mesonzhnik
Natalia Mesonzhnik
IIIrina S. Ilgisonis
Irina S. Ilgisonis
YBYuri N. Belenkov
Yuri N. Belenkov
MKMaria V. Kozhevnikova
Maria V. Kozhevnikova
SASvetlana A. Appolonova
Svetlana A. Appolonova

23 July 2025 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
NMNatalia Moskaleva
Natalia Moskaleva
PRP. M. Rezvanov
P. M. Rezvanov
VSV. M. Samoylov
V. M. Samoylov
VVValeria Varzieva
Valeria Varzieva
SBSabina Baskhanova
Sabina Baskhanova
SASvetlana Appolonova
Svetlana Appolonova
The aim. To investigate the metabolic profile of zebrafish embryos when exposed to drugs with known risks of cardiotoxicity, such as acetaminophen, carbamazepine, salbutamol, ketorolac, bisoprolol, and metoprolol. The analysis is aimed at detecting changes in the level of amino acids (including branched chain BCAAs), products of carnitine metabolism (acylcarnitines) and related metabolic indices reflecting mitochondrial dysfunction, oxidative stress and disorders of the nitric oxide signaling pathway. Materials and methods. Zebrafish embryos were incubated with the test substances in a concentration gradient (0.5–10×NOEC). A quantitative targeted metabolomics analysis was performed using high-performance liquid chromatography with tandem mass spectrometry (HPLC–MS/MS) with a panel of 98 metabolites (amino acids, nitric oxide metabolism products, vitamins, nucleosides and acylcarnitines). The obtained concentrations of metabolites were compared with the control (0.1% DMSO). Statistically significant deviations were expressed as the ratio of concentration to control on a base 2 logarithmic scale (log2FC).Results. Changes in concentrations of metabolites under the influence of cardiotoxic drugs were revealed. There was an accumulation of BCAAs (the sum of leucine, isoleucine, valine; log2FC≈0.5–2.2; p <0.05) compared with the control, as well as an increase in the level of acylcarnitines, indicating mitochondrial dysfunction: for example, metoprolol and bisoprolol caused an increase in the ratio of the sum of acylcarnitines to free carnitine by more than 4–6 times (log2FC=+3.8 for bisoprolol and -1.27 for metoprolol; p <0.01), as well as accumulation of long-chain acylcarnitines. Pronounced changes in indicators related to oxidative stress were noted: in the samples after exposure to beta-1 blockers (bisoprolol, metoprolol) and ketorolac, the concentration of methionine sulfoxide (by 80–130%, p < 0.01), the product of methionine oxidation, and the ratio of methionine sulfoxide/methionine increased, whereas when exposed to salbutamol, on the contrary, the level of methionine sulfoxide decreased (-120%, p <0.01), indicating a multidirectional effect on the oxidative status. Violations of the nitric oxide signaling pathway were reflected in an increase in the level of asymmetric dimethylarginine. Conclusion. Each of the analyzed compounds produced a specific metabolic “imprint” in Zebrafish samples, reflecting the mechanisms of their cardiotoxicity. An increase in BCAA levels and related indicators indicates a violation of myocardial energy metabolism, the accumulation of long-chain acylcarnitines indicates incomplete beta-oxidation of fatty acids. An increase in the concentration of ADMA is associated with endothelial dysfunction, and an increase in methionine sulfoxide is associated with increased oxidative stress.

3 December 2025 in Drug development & registration
Verified
Journal Article
Open access
PDF file
VVValeria Varzieva
Valeria Varzieva
KSKsenia Shestakova
Ksenia Shestakova
ABA. A. Boldin
A. A. Boldin
DKDaria Kutsakina
Daria Kutsakina
YKYu. Yu. Kirichenko
Yu. Yu. Kirichenko
ЮКЮ. Ю. Кириченко
Ю. Ю. Кириченко
Introduction. Multiple myeloma (MM) is a malignant disease of plasma cells characterized by marked heterogeneity of the clinical course and variability in response to treatment. Metabolomic analysis, which reflects the totality of small molecules in biological fluids, opens up new possibilities for the search for diagnostic and prognostic biomarkers. Aim. To evaluate metabolomic profiles of patients with multiple myeloma (MM) and to identify metabolic markers associated with the efficacy of polychemotherapy. Materials and methods. The study was conducted from September 2022 to May 2025 at the Department of Hospital Therapy No. 1 of Sechenov University. We performed targeted analysis of plasma metabolites in 29 pre-treatment MM patients and 30 healthy volunteers (controls). Patients were divided into response and no response groups based on the results of therapy with VCD protocol after three courses. Results and discussion. Significant differences in metabolomic profiles of MM patients compared to controls were found. MM patients showed increased tryptophan catabolism via the kynurenine pathway (~41 % increase in kynurenine/tryptophan ratio, ~80 % decrease in serotonin levels), changes in urea and nitric oxide cycle metabolites (~28 % decrease in arginine, ~5.3-fold increase in asymmetric dimethylarginine), and amino acid imbalances (decrease in serine, aspartate, BCAA) and a significant increase in total acylcarnitines (~1.4-fold higher than control). The baseline metabolic profile also differed between patients with different treatment outcomes: before treatment, patients who subsequently showed a clinical response had lower levels of several acylcarnitines and tryptophan breakdown products (e.g. anthranilic acid), whereas patients without response showed decreased levels of 5-hydroxytryptophan, indole-3-lactic acid and histidine. Conclusions. Metabolomic analysis revealed characteristic metabolic alterations in MM reflecting activation of immunometabolic pathways (tryptophan kynurenine pathway, arginine metabolism) and impaired energy and amino acid regulation. The results indicate the potential prognostic significance of metabolites: a number of biomarkers (e.g. tryptophan derivatives, acylcarnitines) may be associated with chemotherapy sensitivity. The findings open the prospects for further research on metabolic approaches in MM monitoring and therapy.

20 December 2025 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
VVValeria Varzieva
Valeria Varzieva
ABAndrey Boldin
Andrey Boldin
KSKsenia Shestakova
Ksenia Shestakova
SBSabina Baskhanova
Sabina Baskhanova
VSViktor Samoylov
Viktor Samoylov
SASvetlana Appolonova
Svetlana Appolonova
Background. Metabolomics studies in oncology provide a deeper understanding of the biochemical processes associated with tumor growth and the body's response to treatment. In patients with lymphoma, systemic metabolic changes remain poorly understood despite their high clinical significance. Aim. To evaluate changes in the metabolomic profile of blood plasma in patients with lymphoma at various stages of polychemotherapy (PCT) and compare them to those of healthy volunteers. Materials and methods. The study included 18 patients with lymphoma from whom blood was collected before treatment and after the first and third courses of PCT. The control group included 30 healthy volunteers. The analysis was performed by high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) and included measurements of amino acids, tryptophan and arginine derivatives, and acylcarnitines. Statistical processing was performed using analysis of variance and principal component analysis. Results. Prior to therapy, patients showed characteristic metabolic disorders: activation of the kynurenine pathway of tryptophan metabolism, a decrease in arginine, and an increase in its methylated derivatives, as well as shifts in the amino acid and acylcarnitine profiles. During PCT, partial normalization of these indicators was observed, especially for the serotonin-melatonin cascade and kynurenine metabolites. Conclusion. Metabolomics analysis revealed characteristic biochemical changes in patients with lymphoma and their changes over time during treatment. The data obtained emphasize the potential of metabolomics as a tool for monitoring treatment effectiveness and patient condition in oncology.

16 April 2026 in Russian Journal of Cardiology
Verified
Journal Article
Closed access
ISI. Ya. Sokolova
I. Ya. Sokolova
SMSh. M. Murtuzaliev
Sh. M. Murtuzaliev
PMPavel Markin
Pavel Markin
SASvetlana Appolonova
Svetlana Appolonova
TKT. Yu. Kulagina
T. Yu. Kulagina
III. S. Ilgisonis
I. S. Ilgisonis
Aim . To study the profile and long-term changes of recommended markers of cardiotoxicity (high-sensitivity troponin I (hs-TnI), N-terminal pro-brain natriuretic peptide (NT-proBNP)), markers of endothelial dysfunction (endothelin-1 (ET-1)), systemic inflammation (C-reactive protein (CRP), interleukin-6 (IL-6)) and left ventri­cular (LV) structural and functional characteristics in patients with lymphomas 12 months after the start of multiagent chemotherapy, as well as to evaluate the relationship between the obtained data. Material and methods . The study included patients with newly diagnosed lymphomas (n=30) as follows: 18 men (60%); mean age — 52 [36; 64] years. Hodgkin lymphoma was diagnosed in 8 patients (26,7%), non-Hodgkin lymphomas — in 22 (73,3%). All patients underwent an assessment of laboratory markers (hs-TnI, NT-proBNP, ET-1, CRP, IL-6) and LV structural and functional parameters using speckle tracking echocardiography at baseline and 12 months after the start of treatment. Results . After 12 months from the start of chemotherapy, no significant changes in the levels of hs-TnI and NT-proBNP were noted. A significant decrease in the le­vels of CRP and IL-6 was observed as follows: from 5,94 [2,98; 34,00] mg/L to 1,31 [0,85; 5,98] mg/L (p=0,002) and from 12,20 [9,95; 12,75] pg/ml to 5,87 [4,7; 7,04] pg/ml (p=0,05), respectively. A significant increase in the median ET-1 level was also noted as follows: 3,46 [2,39; 4,12] ng/ml initially and 11,26 [7,02; 15,5] ng/ml after 12 months (p<0,001). According to echocardiography data, reliable chan­ges of the parameters of LV diastolic function were revealed: a decrease in E/A (p<0,001), an increase in E/e’ (p<0,001), an increase in isovolumic relaxation time (p<0,001) and left atrial volume index (LAVI) (p<0,001). A moderate correlation was found between the ET-1 level and the LAVI (r=0,5; p=0,031) and E/A (r=0,6; p=0,02) values. ROC curve analysis demonstrated the significance of the baseline ET-1 level as a predictor of a E/A decrease (AUC — 0,827±0,096; 95% CI: 0,638-1,000) and LV global longitudinal strain (AUC — 0,747±0,094; 95% CI: 0,563-0,932) after 12-month follow-up. Conclusion . The obtained data suggest the development of diastolic dysfunction (DD) during the first year after the initiation of chemotherapy in patients with lymphomas. The identified relationship between ET-1 levels and diastolic dysfunction parameters allows us to consider ET-1 as a potential predictor of LV DD in these patients, necessitating their monitoring before and long-term after chemotherapy. In the context of the search for the most effective methods for preventing and predicting cardiovascular toxicity after antitumor therapy, it seems appropriate to further study the relationship between endothelial dysfunction, diastolic dysfunction, heart failure with preserved ejection fraction, and other long-term cardiovascular events in cancer patients after treatment.

27 February 2023 in Drug development & registration
Verified
Journal Article
Open access
PDF file
VVValeria Varzieva
Valeria Varzieva
NMNatalia Mesonzhnik
Natalia Mesonzhnik
ABAnton Belushenko
Anton Belushenko
NBN. L. Bochkareva
N. L. Bochkareva
SASvetlana Appolonova
Svetlana Appolonova
Introduction. Highly glycosylated proteins are the most abundant class of modern biopharmaceuticals. A majority of such therapeuticals produced by Russian biopharmaceutical companies is biosimilars. The foundation of biosimilar manufacturing is analytical assessment of structure equivalence to an original molecule. Fc-fusions present a challenge due to their structural properties. The only biosimilar of this kind registered in Russia is etanercept – a fusion of tumor necrosis factor receptor α and Fc-fragment of IgG1. Existing approaches widely used in protein analysis do not allow accurate and reliable description of glycoylation of these proteins. Development of new approaches and principles of such analysis is necessary, as the changes in biosimilar’s molecular structure can seriously affect its efficacy and safety.Aim. Development of double proteolysis approaches for glycopeptide mapping of Fc-fusion protein etanercept using Arg-C protease.Materials and methods. Etanercept was subjected to enzymatic hydrolysis using trypsin in combination with Arg-C or Asp-N. The resulting peptides were analyzed using HPLC-MS system Xevo G2-XS QTOF (Waters Corporation, USA). The conformation of glycan structure was performed via analysis of fragment spectra of glycopeptides, acquired with high collision energy mode (MS E ). UNIFI (version 1.8) with biopharmasuetical assessment setting (Waters Corporation, USA) was used to analyze the peptide maps.Results and discussion. It was found that using the combination of trypsin with protease Arg-C leads to reliable results Using the developed approach we successfully determined the majority of O-glycosylation sites and types of O-glycans. It was shown that for an effective O-glycopeptide maping N-deglycosylation stage is required. Most abundant N-glycan structures were identified for each of three N-glycosylation sites (N149, N171, N317). It was determined, that the combination of trypsin with Arg-C allows identification of three-antenna forms despite the presence of O-glycosylation site on the analyzed peptide. General N-glycosylation profile shows comparability of results for both approaches.Conclusion. As a result of this research we developed glycopeptide mapping approaches in which a combination of proteases is used. Using these methods sites of N- and O-glycosilation and glycofoms of etanercept were accurately and reproducibly determined. Developed procedures can be applied to other types of Fc-fusion proteins, making it of broader appeal and benefit to the overall biopharmaceutical industry. These approaches provide comprehensive information useful for structure-function studies and of potential value for product comparability measurements and possibly even future manufacturing control strategies.